6 results about "DEAE-Cellulose" patented technology

This invention discloses the application of Uncaria rhynchophylla neutral polysaccharide URP-W in the preparation of anti-glioma drugs, belonging to the field of anti-tumor technology of medicinal plant polysaccharides. The invention obtains a crude polysaccharide extract from Uncaria rhynchophylla through hot water extraction and ethanol precipitation, followed by purification using a DEAE cellulose column and G200 dextran gel to obtain Uncaria rhynchophylla neutral polysaccharide URP-W. The monosaccharide composition of URP-W includes arabinose, rhamnose, galactose, glucose, xylose, mannose, galacturonic acid, and mannuronic acid in a molar ratio of 17.99:6.32:21.71:27.17:2.56:7.57:16.20:0.49. Experiments have shown that URP-W can inhibit the proliferation of gliomas and induce apoptosis, exhibiting significant anti-tumor activity against glioma cells, providing a new drug raw material and treatment method for the clinical treatment of gliomas.

The application discloses a chaga acidic polysaccharide IOP-2 with anti-thyroid cancer activity and application thereof, and belongs to the field of biological medicines. The application adopts a method for extracting chaga polysaccharide by boiling water and precipitating chaga polysaccharide by ethanol, and combines DEAE cellulose column purification technology, and successfully realizes separation of chaga polysaccharide by using the principle that macromolecular polysaccharide is insoluble in organic solvents, and obtains chaga acidic polysaccharide IOP-2 with anti-thyroid cancer activity. The monosaccharide composition of the chaga acidic polysaccharide IOP-2 includes fucose 0.71%, rhamnose 3.33%, arabinose 2.18%, galactose 2.92%, glucose 80.59%, xylan 3.46% and mannose 6.81% in terms of molar percentage. The significant effect of the chaga acidic polysaccharide IOP-2 on anti-thyroid cancer is verified through in-vivo and in-vitro experiments, and a new treatment method is provided for clinical treatment of thyroid cancer.

The application discloses application of Uncariae Ramulus Cruda acidic polysaccharide URP-1 in preparation of anti-prostate cancer drugs and belongs to the technical field of medicinal plant polysaccharide anti-tumor. The total Uncariae Ramulus Cruda polysaccharide is obtained from Uncariae Ramulus Cruda through a method of boiling water extraction and ethanol precipitation, then the total polysaccharide is purified through DEAE cellulose and dextran gel G200 to obtain Uncariae Ramculus Cruda acidic polysaccharide URP-1. The components of the URP-1 include arabinose, rhamnose, galactose, glucose, mannose and galacturonic acid, and the molar percentages are 28.68%, 11.08%, 29.55%, 19.00%, 4.47% and 7.22% respectively. It is found through experiments that the Uncariae Ramulus Cruda acidic polysaccharide URP-1 has significant anti-tumor activity on DU 145 cells, and provides a new drug raw material and treatment method for clinical treatment of prostate cancer.

The invention belongs to the technical field of medicines, and particularly relates to oral liquid for promoting digestion, relieving indigestion and supplementing calcium, iron and zinc and a preparation method thereof. Comprising the following steps: extracting and purifying rorippa formosana polysaccharide; preparing an auxiliary digestion promoting agent; preparing an aromatic digestion promoting agent; and compounding the oral liquid. The preparation method comprises the following steps: extracting rorippa formosana crude polysaccharide from rorippa formosana through water extraction and alcohol precipitation, then carrying out chromatography on the rorippa formosana crude polysaccharide by using a DEAE cellulose DE-52 column to prepare rorippa formosana polysaccharide, acetylating the rorippa formosana polysaccharide, and compounding with a mixed concentrated solution obtained by water extraction and concentration of hawthorn, coix seed and Chinese yam to obtain the rorippa formosana polysaccharide compound. The prepared auxiliary digestion promoting agent is applied to the oral liquid, so that the effects of promoting digestion and relieving stasis can be enhanced, and the absorption and utilization of the body on effective components of food can be promoted, thereby effectively improving and treating the dyspepsia problem of the human body, improving the appetite of children, and avoiding the phenomena of malnutrition and immunity decline caused by dyspepsia and poor appetite.

The invention provides a polypeptide medicine for treating osteoporosis and a preparation method of the polypeptide medicine, and belongs to the technical field of biological medicine, and the polypeptide medicine comprises the following components: Pleurotus niger peptide, soybean meal protein peptide, a Chinese sumac leaf-broussonetia papyrifera leaf extract, a ulmus pumila leaf-Sophora japonica leaf extract and the like. The method comprises the following steps: sequentially fermenting Pleurotus tuber-regium through candida utilis and lactobacillus plantarum, carrying out enzymolysis through ficin protease, and purifying through a G-50 sephadex column to obtain the Pleurotus tuber-regium peptide. The soybean meal protein peptide is prepared by sequentially carrying out enzymolysis on soybean meal through cellulase, trypsin and bromelain and purifying through an LH-60 sephadex column. The Chinese sumac leaves and the paper mulberry leaves are extracted through an ethanol aqueous solution and purified through a DEAE cellulose column, and the Chinese sumac leaf-paper mulberry leaf extract is prepared. The ulmus pumila leaves and the sophora japonica leaves are sequentially subjected to enzymolysis through cellulase, pepsin and ficin, and purification is conducted through a 732 cation exchange resin column to prepare the ulmus pumila leaf-sophora japonica leaf extract. The components are compounded, so that the bone resorption process is blocked, bone formation and mineralization are strengthened, and osteoporosis is improved.

The application provides a detection reagent for frozen semen of Huai pig, and first acquires the raw semen, and then carries out the following steps: ammonium sulfate fractionation precipitation, DEAE cellulose filter gel column chromatography, CM Sepharose FastFlow gel chromatography and Sephadex G-100 chromatography to separate and purify the NAGase of the semen of the Huai pig, and monoclonal antibodies JN21 and JN37 are prepared by taking the NAGase as an antigen, and the monoclonal antibodies can specifically recognize the NAGase of the Huai pig. The prepared double-antibody sandwich ELISA kit can rapidly and quantitatively detect the NAGase content in the semen of the Huai pig, and provides a new thought for Huai pig breeding and purification and rejuvenation. The kit is convenient to operate, low in use cost, good in repeatability and suitable for being widely applied.